Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of sarcomas
3.2.1.2 Advancements in research and development
3.2.1.3 Awareness and early detection initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 High development costs
3.2.2.2 Adverse effects and toxicity
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Disease Indication, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Soft tissue sarcoma
5.2.1 Leiomyosarcoma
5.2.2 Liposarcoma
5.2.3 Synovial sarcoma
5.2.4 Fibrosarcoma
5.2.5 Angiosarcoma
5.2.6 Epithelioid sarcoma
5.2.7 Kaposi's sarcoma
5.2.8 Other soft tissue sarcomas
5.3 Bone sarcoma
5.3.1 Osteosarcoma
5.3.2 Ewing sarcoma
5.3.3 Chondrosarcoma
Chapter 6 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Chemotherapy
6.3 Targeted therapy
6.4 Immunotherapy
6.5 Other treatments
Chapter 7 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Branded
7.3 Generic
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott laboratories
10.2 AbbVie Inc.
10.3 Amneal Pharmaceuticals Inc.
10.4 Bausch Health Companies Inc.
10.5 Bayer AG
10.6 Baxter International Inc.
10.7 Bristol-Myers Squibb Company
10.8 GSK plc
10.9 Hikma Pharmaceuticals PLC
10.10 Johnson & Johnson
10.11 Lupin Limited
10.12 MERCK & CO., INC.
10.13 Novartis AG
10.14 Pfizer Inc.
10.15 Sun Pharmaceutical Industries Ltd
